Equities

ALX Oncology Holdings Inc

ALXO:NSQ

ALX Oncology Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.24
  • Today's Change0.10 / 4.67%
  • Shares traded46.75k
  • 1 Year change-54.84%
  • Beta1.0241
Data delayed at least 15 minutes, as of Sep 19 2024 16:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments183266364
Total Receivables, Net1.00----
Total Inventory------
Prepaid expenses4.924.763.35
Other current assets, total------
Total current assets189271367
Property, plant & equipment, net119.793.40
Goodwill, net------
Intangibles, net------
Long term investments3517--
Note receivable - long term------
Other long term assets7.589.039.77
Total assets243306380
LIABILITIES
Accounts payable8.598.073.76
Accrued expenses262011
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.730.290.43
Other current liabilities, total0.630.17--
Total current liabilities362815
Total long term debt119.390.28
Total debt129.680.71
Deferred income tax------
Minority interest------
Other liabilities, total5.635.311.56
Total liabilities534317
SHAREHOLDERS EQUITY
Common stock0.050.040.04
Additional paid-in capital676590565
Retained earnings (accumulated deficit)(486)(325)(202)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.26(0.85)--
Total equity190263363
Total liabilities & shareholders' equity243306380
Total common shares outstanding504141
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.